When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they'd stumbled upon a revolutionary tool researchers could ...
R. Danny Huntington, Anh-Thu Lam, Ph.D. The Patent Trial and Appeal Board (PTAB) has reaffirmed its earlier priority determination in favor of the Broad Institute in the long-running interference ...
Development of bespoke therapies has been a driving goal in medical research. This year, the announcement of the first patient treated with personalized CRISPR therapy, Baby KJ, highlights this ...
The CRISPR gene editing market is estimated at USD 4 billion in 2025 and is projected to reach USD 22 billion by 2035, expanding at a CAGR of 18.6% during the forecast period 2026–2035. The market is ...
CRISPR Therapeutics is obviously a biopharma name -- but it's a unique one. Co-founder Emmanuelle Charpentier and her research collaborator Jennifer Doudna co-invented the CRISPR/Cas9 gene-editing ...
When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they’d stumbled upon a revolutionary tool researchers could ...
The biotech has won approval for one of the few gene-editing therapies on the market. Several more therapies based on the same science are in the works. Like most young biopharma companies, this one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results